280 related articles for article (PubMed ID: 7828366)
1. Development of oral vaccines to stimulate mucosal and systemic immunity: barriers and novel strategies.
Shalaby WS
Clin Immunol Immunopathol; 1995 Feb; 74(2):127-34. PubMed ID: 7828366
[TBL] [Abstract][Full Text] [Related]
2. A novel mucosal vaccine targeting Peyer's patch M cells induces protective antigen-specific IgA responses.
Shima H; Watanabe T; Fukuda S; Fukuoka S; Ohara O; Ohno H
Int Immunol; 2014 Nov; 26(11):619-25. PubMed ID: 24908678
[TBL] [Abstract][Full Text] [Related]
3. Routes of immunization and antigen delivery systems for optimal mucosal immune responses in humans.
Mestecky J; Michalek SM; Moldoveanu Z; Russell MW
Behring Inst Mitt; 1997 Feb; (98):33-43. PubMed ID: 9382757
[TBL] [Abstract][Full Text] [Related]
4. Oral Vaccination Through Peyer's Patches: Update on Particle Uptake.
Pais Soares EF; Fernandes Borges OM
Curr Drug Deliv; 2018; 15(3):321-330. PubMed ID: 28847272
[TBL] [Abstract][Full Text] [Related]
5. Induction of HSV-gD2 specific CD4(+) cells in Peyer's patches and mucosal antibody responses in mice following DNA immunization by both parenteral and mucosal administration.
Shroff KE; Marcucci-Borges LA; de Bruin SJ; Winter LA; Tiberio L; Pachuk C; Snyder LA; Satishchandran C; Ciccarelli RB; Higgins TJ
Vaccine; 1999 Sep; 18(3-4):222-30. PubMed ID: 10506646
[TBL] [Abstract][Full Text] [Related]
6. Recent advances in mucosal delivery of vaccines: role of mucoadhesive/biodegradable polymeric carriers.
Mishra N; Goyal AK; Tiwari S; Paliwal R; Paliwal SR; Vaidya B; Mangal S; Gupta M; Dube D; Mehta A; Vyas SP
Expert Opin Ther Pat; 2010 May; 20(5):661-79. PubMed ID: 20345332
[TBL] [Abstract][Full Text] [Related]
7. [Uniqueness of the mucosal immune system for the development of prospective mucosal vaccine].
Kunisawa J; Gohda M; Kiyono H
Yakugaku Zasshi; 2007 Feb; 127(2):319-26. PubMed ID: 17268152
[TBL] [Abstract][Full Text] [Related]
8. New generation of mucosal adjuvants for the induction of protective immunity.
Yuki Y; Kiyono H
Rev Med Virol; 2003; 13(5):293-310. PubMed ID: 12931340
[TBL] [Abstract][Full Text] [Related]
9. Vaccine-containing biodegradable microspheres specifically enter the gut-associated lymphoid tissue following oral administration and induce a disseminated mucosal immune response.
Eldridge JH; Meulbroek JA; Staas JK; Tice TR; Gilley RM
Adv Exp Med Biol; 1989; 251():191-202. PubMed ID: 2610110
[TBL] [Abstract][Full Text] [Related]
10. Targeting of mucosal vaccines to Peyer's patch M cells.
Frey A; Neutra MR
Behring Inst Mitt; 1997 Feb; (98):376-89. PubMed ID: 9382762
[TBL] [Abstract][Full Text] [Related]
11. Novel vaccination strategies for the control of mucosal infection.
Husband AJ
Vaccine; 1993; 11(2):107-12. PubMed ID: 8438609
[TBL] [Abstract][Full Text] [Related]
12. Systemic administration of RANKL overcomes the bottleneck of oral vaccine delivery through microfold cells in ileum.
Maharjan S; Singh B; Jiang T; Yoon SY; Li HS; Kim G; Gu MJ; Kim SJ; Park OJ; Han SH; Kang SK; Yun CH; Choi YJ; Cho CS
Biomaterials; 2016 Apr; 84():286-300. PubMed ID: 26851393
[TBL] [Abstract][Full Text] [Related]
13. Soluble RANKL expression in Lactococcus lactis and investigation of its potential as an oral vaccine adjuvant.
Kim JI; Park TE; Maharjan S; Li HS; Lee HB; Kim IS; Piao D; Lee JY; Cho CS; Bok JD; Hong ZS; Kang SK; Choi YJ
BMC Immunol; 2015 Nov; 16():71. PubMed ID: 26608025
[TBL] [Abstract][Full Text] [Related]
14. New perspectives in vaccine development: mucosal immunity to infections.
McGhee JR; Kiyono H
Infect Agents Dis; 1993 Apr; 2(2):55-73. PubMed ID: 8162356
[TBL] [Abstract][Full Text] [Related]
15. Towards targeting strategies for oral immunization--identification of marker antigens in rat M cells.
Rautenberg K; Cichon C; Schmidt MA
Behring Inst Mitt; 1997 Feb; (98):361-75. PubMed ID: 9382761
[TBL] [Abstract][Full Text] [Related]
16. Adjuvants and delivery systems based on polymeric nanoparticles for mucosal vaccines.
Jin Z; Gao S; Cui X; Sun D; Zhao K
Int J Pharm; 2019 Dec; 572():118731. PubMed ID: 31669213
[TBL] [Abstract][Full Text] [Related]
17. Mucosal delivery of native and recombinant protein vaccines against Trichostrongylus colubriformis.
McClure SJ
Int J Parasitol; 2009 Apr; 39(5):599-606. PubMed ID: 18952092
[TBL] [Abstract][Full Text] [Related]
18. M cell-targeting strategy enhances systemic and mucosal immune responses induced by oral administration of nuclease-producing L. lactis.
Takahashi K; Yano A; Watanabe S; Langella P; Bermúdez-Humarán LG; Inoue N
Appl Microbiol Biotechnol; 2018 Dec; 102(24):10703-10711. PubMed ID: 30310964
[TBL] [Abstract][Full Text] [Related]
19. Approaches to tuberculosis mucosal vaccine development using nanoparticles and microparticles: a review.
Caetano LA; Almeida AJ; Gonćalves LM
J Biomed Nanotechnol; 2014 Sep; 10(9):2295-316. PubMed ID: 25992458
[TBL] [Abstract][Full Text] [Related]
20. [Recent progress for the development of mucosal vaccine].
Nochi T; Kiyono H
Tanpakushitsu Kakusan Koso; 2009 Jun; 54(8 Suppl):1089-95. PubMed ID: 21089546
[No Abstract] [Full Text] [Related]
[Next] [New Search]
